{
  "drug_name": "Ceftazidime",
  "tradename": "Fortaz, Tazicef, Tazidime",
  "usage_and_dosing": {
    "general": [
      "Ceftazidime is a 3rd generation cephalosporin with activity against P. aeruginosa. In vitro antibacterial spectrum includes many other aerobic gram-negative bacilli.",
      "Poor in vitro activity against gram-positive bacteria.",
      "Susceptible to inactivation by aerobic gram-negative bacteria that synthesize extended spectrum beta-lactamases (ESBLs).",
      "Protocol for ceftazidime desensitization.",
      "See also ceftazidime-avibactam."
    ],
    "adult_dose": {
      "usual_dose": "1-2 gm IV/IM q8-12h",
      "other_dosing": "Continuous, Extended Infusion Dosing, Intraperitoneal Drug Dosing"
    },
    "pediatric_dose": {
      "standard": "150-200 mg/kg/day (divided q8h)",
      "cf": "300 mg/kg/day (divided q8h)",
      "max_day": "6 gm"
    }
  },
  "renal_adjustment": {
    "half_life_normal": "1.9",
    "half_life_esrd": "13-25",
    "dose_renal_function_normal": "1-2 gm IV q8-12h",
    "crcl_or_egfr": "CrCl >50: No dosage adjustment. CrCl 10-50: 1-2 gm q12-24h. CrCl <10: 1-2 gm q24h",
    "hemodialysis": "0.5-1 gm q24h (AD on dialysis days)",
    "capd": "No data",
    "crrt": "1-2 gm q8-12h 40",
    "sled": "2 gm q12h 49"
  },
  "hepatic_adjustment": {
    "mild_impairment_child_pugh_a": "No dosage adjustment",
    "moderate_impairment_child_pugh_b": "No dosage adjustment",
    "severe_impairment_child_pugh_c": "No dosage adjustment"
  },
  "other_adjustment": [
    "ECMO: See ECMO Drug Dosing Adjustment.",
    "Obesity: see Obesity Dosing Adjustments."
  ],
  "adverse_effects": [
    "Hypersensitivity (e.g., rash, anaphylaxis)",
    "Shares the same R1 side chain as Aztreonam and Cefiderocol, thus cross-allergenicity may occur. See Drug Allergy: Penicillins, Cephalosporins, Overview for details.",
    "Possible photosensitivity.",
    "Excessive use may result in increased incidence of C. difficile-associated diarrhea and/or selection of Vancomycin-resistant E. faecium.",
    "See Cephalosporins, Overview."
  ],
  "pregnancy_risk": {
    "fda_risk_category": "No evidence of toxicity in humans or animals",
    "lactation": "Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",
    "footnote": "Capital letter = Old FDA risk category; Text = New FDA risk category"
  },
  "antimicrobial_spectrum": {
    "preferred": ["Pseudomonas aeruginosa"],
    "alternative": []
  },
  "pharmacology": {
    "pk_pd_index": "T>MIC",
    "preparations": "Injection",
    "food_recommendation": null,
    "oral_absorption_percent": null,
    "tmax_hr": null,
    "peak_serum_conc_ug_ml": "69 (1 gm IV, SD)",
    "peak_urine_conc_ug_ml": "No data",
    "protein_binding_percent": "<10",
    "volume_of_distribution_vd_l_kg_vss": "0.24 L/kg (Vss)",
    "avg_serum_half_life_hr": "1.9",
    "elimination": "Renal",
    "bile_penetration_percent": "13-54",
    "csf_blood_percent": "20-40",
    "therapeutic_levels_in_csf": "Yes",
    "auc_ug_hr_ml": "127 (1 gm IV, 0-inf)"
  },
  "major_drug_interactions": [
    "No significant interactions"
  ]
}
